Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACCShell Companies
+$0.00 today
- Market cap
- $263.53M
- Beta
- -0.04
- P/E (TTM)
- 29.1
- EPS (TTM)
- $0.37
Volume 0.00M
Average 0.01M
OACC Interest Income
Income earned on cash, deposits, and investments held by the company.
Oaktree Acquisition Corp. III Life SciencesNASDAQ: OACC
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $1.85M fell 12.0% year over year. Sequentially, it fell 9.5% from the prior quarter.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 8.48M USD
- Year-over-year change
- +434.0%
- 1-year CAGR
- +434.0%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.48M | +434.0% |
| FY2024 | 2024-12-31 | 1.59M | — |
Interest Income vs competitors
How OACC compares with its peers on the latest reported figures
- OACC's LTM Mar 2026 interest income of $8.23M is the 5th highest of the 10 companies compared; the peer median is $6.98M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
MBAVM3-Brigade Acquisition V Corp. Class A Ordinary shares | LTM Mar 2026 | $11.88M | +35.5% | — | — |
| LTM Mar 2026 | $9.86M | — | — | — | |
| LTM Mar 2026 | $9.36M | +230.4% | +228.5% | — | |
| LTM Mar 2026 | $8.4M | — | — | — | |
OACCOaktree Acquisition Corp. III Life Sciences | LTM Mar 2026 | $8.23M | — | — | — |
| LTM Mar 2026 | $6.98M | +177.3% | +14.4% | — | |
| LTM Mar 2026 | $2.49M | — | — | — | |
| LTM Mar 2026 | $2.27M | — | — | — | |
AACBArtius II Acquisition Inc. Class A Ordinary Shares | LTM Mar 2026 | $988.46K | — | — | — |
COPLCopley Acquisition Corp | LTM Mar 2026 | $49.48 | — | — | — |
| Peer median (excluding OACC) | $6.98M | +177.3% | +121.4% | — | |
Competitors are the stored peer set for OACC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Gross Margin | — | — |
| Research & Development | 0 | 0 |
| Selling, General & Admin | 704 | 1.2M |
| Operating Expenses | 704 | 1.2M |
| Depreciation & Amortization | 704 | 0 |
| EBITDA | (351.81K) | (1.2M) |
| EBITDA Margin | — | — |
| Operating Income | (703) | (1.2M) |
| Operating Margin | — | — |
| Interest Income | 1.59M | 8.48M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 3.37K | 8.48M |
| Income Before Tax | 2.66K | 7.29M |
| Pre-Tax Margin | — | — |
| Income Tax Expense | 0 | 0 |
| Net Income | 2.66K | 7.29M |
| Net Margin | — | — |
| EPS (Basic) | 0.05 | 0.30 |
| EPS (Diluted) | 0.05 | 0.30 |
| Weighted Avg Shares | 24.58M | 19.2M |
| Weighted Avg Shares (Diluted) | 24.58M | 19.2M |
Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACC
Intrinsic Alpha fair value
Locked
Current Price
$10.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.